Anchor Capital Advisors’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-2,300
Closed -$206K 290
2018
Q3
$206K Buy
+2,300
New +$203K 0.01% 263
2018
Q2
Sell
-2,300
Closed -$205K 323
2018
Q1
$205K Hold
2,300
0.01% 297
2017
Q4
$240K Hold
2,300
0.01% 256
2017
Q3
$335K Sell
2,300
-83
-3% -$11.3K 0.01% 229
2017
Q2
$309K Sell
2,383
-67
-3% -$8.21K 0.01% 230
2017
Q1
$305K Sell
2,450
-250
-9% -$29.9K 0.01% 240
2016
Q4
$313K Hold
2,700
0.01% 241
2016
Q3
$282K Hold
2,700
0.01% 252
2016
Q2
$266K Sell
2,700
-22
-0.8% -$2.28K 0.01% 262
2016
Q1
$272K Sell
2,722
-54
-2% -$5.56K 0.01% 254
2015
Q4
$332K Hold
2,776
0.01% 249
2015
Q3
$300K Sell
2,776
-9
-0.3% -$1.12K 0.01% 242
2015
Q2
$322K Sell
2,785
-211
-7% -$24.1K 0.01% 248
2015
Q1
$345K Buy
2,996
+731
+32% +$87.3K 0.01% 249
2014
Q4
$253K Sell
2,265
-560
-20% -$59.1K 0.01% 290
2014
Q3
$268K Sell
2,825
-251
-8% -$22.7K 0.01% 289
2014
Q2
$264K Sell
3,076
-112
-4% -$8.52K 0.01% 293
2014
Q1
$223K Sell
3,188
-64
-2% -$5.07K ﹤0.01% 300
2013
Q4
$275K Sell
3,252
-176
-5% -$13.9K 0.01% 277
2013
Q3
$264K Buy
+3,428
New +$240K 0.01% 275

Other funds holding CELG

Anchor Capital Advisors's CELG Position: Q4 2018 in Review

Anchor Capital Advisors sold out of Celgene Corp (CELG) in Q4 2018, closing a stake of 2,300 shares — an estimated $206K sold.

Anchor Capital Advisors first reported a position in CELG in Q3 2013 and held it in 20 quarters. The position peaked at $345K in Q1 2015. 1,317 funds tracked by Wall St. Rank hold CELG as of Q4 2018.

  • Anchor Capital Advisors reported no remaining Celgene Corp position as of Q4 2018 after selling out during the quarter.
  • Anchor Capital Advisors sold 2,300 Celgene Corp shares in Q4 2018, an estimated $206K.
  • Anchor Capital Advisors first reported a position in Celgene Corp in Q3 2013 and held it in 20 quarters.
  • Anchor Capital Advisors's Celgene Corp position peaked at $345K in Q1 2015.
  • 1,317 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2018.

Based on Anchor Capital Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.